Troubled Alzheimer's player Cortexyme says goodbye to founding team as independent investor takes chairmanship
When Cortexyme’s leadership got on an analyst call last October to discuss the results for their lead Alzheimer’s drugs, many listeners were bewildered.
The trial had unequivocally failed: No difference in cognitive decline was seen between patients on placebo and patients on their drug. There did seem to be an effect on one subgroup that some neurologists found promising, but that was just the tentative basis for a new study, not a decisive result.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.